Operational technology and information technology integration will remain central to pharmaceutical manufacturing strategies in 2026. Being able to connect production systems, quality data, utilities and performance metrics will continue to underpin efforts to improve visibility, consistency and control across operations.

Where things could start to change is how that integration plays out at scale. As programmes mature, a clear pattern is emerging across large, multi-site organisations. Common platforms are often selected at an enterprise level, but implementation is then adapted locally to reflect the realities of individual sites. Over time, those adaptations start to stack up.

This year, more manufacturers could start to feel the consequences of this. Individual facilities will often be operating well, but replicating that success across the wider network becomes harder. Integration projects slow down, costs increase and digital programmes lose momentum once the first group of sites has been delivered.

This won’t be a failure of technology. In most cases, it will come back to earlier decisions around governance and system design. As manufacturers look to extend integration across sites and regions, standardisation and repeatability will matter just as much as flexibility. How organisations strike that balance is likely to be one of the defining factors in whether digital strategies genuinely scale over the next few years.

Sustainability commitments are now firmly embedded in pharmaceutical manufacturing strategies across Europe. Improving energy efficiency, cutting emissions and strengthening transparency are no longer optional. They are expected.

At the same time, digital infrastructure will continue to expand through 2026. Data volumes are increasing, cloud adoption is accelerating and AI-driven analytics are becoming part of everyday operations across quality, production and supply chain functions.

What many organisations are only just starting to grapple with is the digital footprint that comes with this shift. While Scope 1, 2 and 3 emissions are closely monitored, the energy and emissions impact of large-scale data processing and continuous analysis is not always fully factored into digital decision-making.

This will introduce a new layer of complexity in 2026. Some digital initiatives will deliver clear operational benefits, but they may also drive higher energy consumption elsewhere in the system. As sustainability reporting becomes more detailed and expectations continue to rise, manufacturers will need a clearer view of these trade-offs.

For many, that will mean taking a more considered approach to data strategy. Rather than defaulting to centralised processing, I’m anticipating a growing interest in keeping certain workloads closer to where data is generated. Doing so can reduce unnecessary data movement, limit energy use while still maintaining the levels of compliance and control the industry demands.

Cloud infrastructure has fundamentally changed how pharmaceutical companies manage data, collaborate across regions and deploy new applications. At an enterprise level, its value is well established and will continue to grow through 2026.

There could be more reassessment in how cloud strategies are applied within manufacturing environments. Production operations depend on real-time feedback, deterministic performance and high availability. When large volumes of raw shop-floor data are moved away from the point of use without enough local context, decision-making can slow down and systems can become more fragile than intended.

Manufacturers will need to start asking different questions. Rather than focusing solely on where data can be stored, the emphasis will shift to where it should be processed to best support quality, reliability and speed. That shift reflects a more practical understanding of how manufacturing systems actually operate day to day.

That’s not a rejection of cloud technologies. Instead, it points to more deliberate architectures that combine local and centralised capabilities. The aim is to ensure digital infrastructure supports operations on the factory floor, rather than adding unnecessary complexity.

Pharmaceutical manufacturers continue to invest heavily in digital innovation. New initiatives across manufacturing, quality and supply chain functions are launched every year, and that level of ambition is unlikely to slow in 2026.

Where more organisations could struggle is not in starting these programmes, but in sustaining them. As projects move from pilot phases to broader rollouts, organisational barriers often emerge. Leadership changes, shifting priorities and complex approval processes can stall progress or redirect funding.

Over time, this creates a familiar cycle. Promising initiatives are paused, re-evaluated or rebranded. Each restart may be justified on its own, but the cumulative effect is uneven progress and increasing frustration among operational teams who are trying to make systems work consistently.

Looking ahead, sustaining digital momentum will depend less on technical capability and more on how programmes are governed. Clear ownership, long-term commitment and alignment between strategic intent and operational execution will be critical if digital initiatives are to deliver lasting value.

The wider investment environment will continue to influence manufacturing decisions across Europe in 2026. While some regions remain attractive for expansion, others are viewed more cautiously due to regulatory uncertainty, cost pressures and questions around policy stability.

In this context, digital transformation plays a dual role. It is essential for improving efficiency and competitiveness, but it also represents a long-term commitment that must be justified against uncertain investment horizons.

As a result, manufacturers will become more selective about where and how they invest in digital capabilities. Rather than pursuing large-scale transformation programmes, many will focus on targeted improvements that deliver measurable operational value while preserving flexibility.

This more cautious approach is likely to persist, particularly in regions where policy signals remain mixed. Digital strategies that support adaptability and resilience will be better positioned to withstand shifts in the investment landscape.

The future of pharmaceutical manufacturing will not be defined by any single technology or initiative. Instead, it will be shaped by how effectively organisations align digital priorities with operational reality.

In 2026 and beyond, the most successful strategies will prioritise coherence over complexity. That means designing integration approaches that can be replicated across sites, understanding the sustainability implications of digital infrastructure, and ensuring cloud architectures genuinely support real-time operations.

It also means recognising that digital transformation is an ongoing process, not a series of disconnected projects. Manufacturers that put governance structures in place to sustain progress over time will be better positioned to realise long-term value.

As digital ambition continues to grow, the challenge for pharmaceutical manufacturers will not be doing more. It will be focusing on what matters most, and doing it in a way that can endure.